Clinical Trials Logo

Hematopoietic/Lymphoid Cancer clinical trials

View clinical trials related to Hematopoietic/Lymphoid Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03126864 Terminated - Clinical trials for Acute Myeloid Leukemia

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

Start date: August 4, 2017
Phase: Phase 1
Study type: Interventional

Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn about the safety and tolerability of 3 different doses of CD33-CAR-T cells (referred to throughout the consent as "T-cells") in patients who have CD33-positive acute myeloid leukemia (AML) that is relapsed (has come back) or refractory (has not responded to treatment). CD33-CAR-T is made by genetically modifying (changing) your T-cells (a type of white blood cell). T-cells are genetically changed to help target leukemia cells. This is an investigational study. CD33-CAR-T is not FDA approved or commercially available. It is currently being used for research purposes only. The study doctor can explain how the study drug is designed to work. Up to 39 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT03121534 Terminated - Clinical trials for Hematopoietic/Lymphoid Cancer

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Start date: June 22, 2017
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if blinatumomab can help to control Richter Transformation (RT, a type of blood cancer). The safety of this drug will also be studied. This is an investigational study. Blinatumomab is FDA approved and commercially available for the treatment of acute lymphoblastic leukemia (ALL). It is investigational to use blinatumomab to treat patients with RT. The study doctor can explain how the study drug is designed to work. Up to 21 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT00089089 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas

Start date: September 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of decitabine in treating patients with metastatic or unresectable refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as decitabine, work in different ways to stop cancer cells from dividing so they stop growing or die

NCT ID: NCT00070239 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

Start date: August 2003
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of alvocidib in treating patients with metastatic or unresectable refractory solid tumors or hematologic malignancies. Drugs used in chemotherapy, such as alvocidib, work in different ways to stop cancer cells from dividing so they stop growing or die.